Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
Madrid, ES
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.61% | -7.49% | -26.69% | -21.11% | +3.30% | -3.78% | +13.15% | +45.34% | +27.56% | +321.38% | +546.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.7% Q1'26: -1.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+3.0% Q1'26: -45.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.4% Q1'26: +3.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+23.3% ★ Q1'26: +6.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+18.3% ★ Q1'26: +4.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.72× Q1'26: 1.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 9 Rev. Ana. 8 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
246.01M
est: 247.62M (-0.7%)
|
265.17M
est: 265.79M (-0.2%)
|
275.65M
est: 275.39M (+0.1%)
|
303.20M
est: 301.71M (+0.5%)
|
381.31M
est: 369.61M (+3.2%)
|
419.96M
est: 416.49M (+0.8%)
|
648.68M
est: 629.07M (+3.1%)
|
817.70M
est: 792.01M (+3.2%)
|
829.51M
est: 778.00M (+6.6%)
|
763.75M
est: 765.76M (-0.3%)
|
743.48M
est: 730.98M (+1.7%)
|
777.79M
764.71M – 790.70M
+6.4% YoY
|
913.24M
845.63M – 1.01B
+17.4% YoY
|
1.00B
1.00B – 1.01B
+9.9% YoY
|
1.13B
1.07B – 1.20B
+12.4% YoY
|
1.22B
1.16B – 1.30B
+8.2% YoY
|
| EBITDA |
32.65M
est: 71.82M (-54.5%)
|
35.75M
est: 77.09M (-53.6%)
|
30.58M
est: 79.87M (-61.7%)
|
29.41M
est: 87.51M (-66.4%)
|
60.74M
est: 107.20M (-43.3%)
|
93.28M
est: 120.80M (-22.8%)
|
204.72M
est: 182.46M (+12.2%)
|
281.49M
est: 229.72M (+22.5%)
|
245.81M
est: 233.69M (+5.2%)
|
207.69M
est: 230.01M (-9.7%)
|
203.52M
est: 219.56M (-7.3%)
|
233.62M
229.69M – 237.50M
+6.4% YoY
|
274.31M
254.00M – 302.11M
+17.4% YoY
|
301.33M
300.47M – 302.20M
+9.9% YoY
|
338.72M
322.43M – 360.03M
+12.4% YoY
|
366.65M
349.02M – 389.72M
+8.2% YoY
|
| EBIT |
22.68M
est: 63.23M (-64.1%)
|
28.80M
est: 67.86M (-57.6%)
|
18.54M
est: 70.31M (-73.6%)
|
17.39M
est: 77.04M (-77.4%)
|
42.53M
est: 94.37M (-54.9%)
|
73.39M
est: 106.34M (-31.0%)
|
183.30M
est: 160.62M (+14.1%)
|
258.57M
est: 202.22M (+27.9%)
|
221.36M
est: 207.58M (+6.6%)
|
179.68M
est: 204.32M (-12.1%)
|
173.14M
est: 195.04M (-11.2%)
|
207.53M
204.04M – 210.97M
+6.4% YoY
|
243.66M
225.62M – 268.36M
+17.4% YoY
|
267.67M
266.90M – 268.44M
+9.9% YoY
|
300.88M
286.41M – 319.81M
+12.4% YoY
|
325.69M
310.03M – 346.18M
+8.2% YoY
|
| Net Income |
19.81M
est: 18.22M (+8.7%)
|
26.09M
est: 23.96M (+8.9%)
|
17.24M
est: 14.28M (+20.7%)
|
17.90M
est: 16.25M (+10.1%)
|
39.27M
est: 32.59M (+20.5%)
|
61.06M
est: 55.56M (+9.9%)
|
153.08M
est: 121.75M (+25.7%)
|
199.67M
est: 167.56M (+19.2%)
|
170.34M
est: 148.03M (+15.1%)
|
136.88M
est: 147.04M (-6.9%)
|
140.44M
est: 131.82M (+6.5%)
|
134.80M
126.54M – 147.67M
+2.3% YoY
|
193.74M
157.53M – 216.49M
+43.7% YoY
|
231.61M
201.20M – 289.20M
+19.6% YoY
|
267.63M
250.90M – 289.52M
+15.5% YoY
|
295.98M
277.48M – 320.19M
+10.6% YoY
|
| SGA |
20.96M
est: 15.64M (+34.0%)
|
16.49M
est: 16.78M (-1.8%)
|
17.47M
est: 17.39M (+0.5%)
|
17.35M
est: 19.05M (-8.9%)
|
19.53M
est: 23.34M (-16.3%)
|
11.41M
est: 26.30M (-56.6%)
|
12.71M
est: 39.72M (-68.0%)
|
32.78M
est: 50.01M (-34.5%)
|
147.02M
est: 93.63M (+57.0%)
|
39.43M
est: 92.15M (-57.2%)
|
232.83M
est: 87.97M (+164.7%)
|
93.60M
92.03M – 95.15M
+6.4% YoY
|
109.90M
101.76M – 121.04M
+17.4% YoY
|
120.73M
120.38M – 121.07M
+9.9% YoY
|
135.71M
129.18M – 144.24M
+12.4% YoY
|
146.90M
139.83M – 156.14M
+8.2% YoY
|
| EPS |
0.40
est: 0.36 (+12.6%)
|
0.53
est: 0.47 (+13.4%)
|
0.35
est: 0.28 (+25.6%)
|
0.35
est: 0.32 (+10.4%)
|
0.71
est: 0.64 (+11.7%)
|
1.10
est: 1.08 (+1.5%)
|
2.76
est: 2.37 (+16.2%)
|
3.73
est: 3.27 (+14.1%)
|
3.29
est: 2.84 (+16.0%)
|
2.67
est: 2.85 (-6.2%)
|
2.75
est: 2.44 (+12.6%)
|
2.69
2.47 – 2.89
+10.3% YoY
|
3.71
3.08 – 4.23
+37.6% YoY
|
4.55
3.93 – 5.65
+22.9% YoY
|
5.23
4.91 – 5.66
+14.9% YoY
|
5.79
5.43 – 6.26
+10.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc WTIM.DE | 0.29% | 159.6K | 0.29% |
| 2 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR EGRW.L | 0.29% | 159.6K | 0.29% |
| 3 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.24% | 1.71M | 0.40% |
| 4 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.18% | 1.91M | 0.58% |
| 5 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.18% | 1.32M | 0.33% |
| 6 | Amundi IBEX 35 UCITS ETF Acc CS1.L | 0.17% | 1.78M | 0.30% |
| 7 | Amundi IBEX 35 UCITS ETF Dist LYXIB.MC | 0.17% | 1.78M | 0.30% |
| 8 | Xtrackers Spain UCITS ETF 1C XESP.DE | 0.12% | 348.9K | 0.30% |
| 9 | Xtrackers Spain UCITS ETF 1D XESD.DE | 0.12% | 348.9K | 0.30% |
| 10 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.07% | 2.43M | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Juan Lopez-Belmonte Encina | Chairman & Chief Executive Officer | 2M | male |
| Javier Lopez-Belmonte Encina | First Deputy Chairman, GM of Industrial Operations & Chief Financial Officer | 666.0K | male |
| Ivan Jorge Lopez-Belmonte Encina | Second Deputy Chairman and Chief Commercial & Development Officer | 660.0K | male |
| María Álvarez Solas | Chief Operating Officer | — | female |
| Mercedes Benítez del Castillo Sánchez | Chief Legal Officer | — | female |
| Miguel Ángel Ortega Sánchez | Chief Industrial Officer | — | male |
| Alicia Hurtado Morales | Chief Compliance Officer | — | female |
| Rosario Perucha Pérez | Marketing Director | — | female |
| Francisco Javier Angulo García | Human Resources Manager | — | male |
| Marta Campos Martínez | Head of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ROVI.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
